%20(1).png?width=1200&height=400&name=Copy%20of%20GALEAS%20BLADDER%20-adoption%20in%20practice%20(1200%20x%20400%20px)%20(1).png "Copy of GALEAS BLADDER -adoption in practice (1200 x 400 px) (1)")
Please complete our form to download the latest white paper on the performance of GALEAS™ Bladder, a non-invasive urine test for the detection and monitoring of bladder cancer.
This paper demonstrates the performance of GALEAS Bladder compared to a cystoscopy, including:
- 92% sensitivity for NMIBC and MIBC, compared to 84% for a cystoscopy
- 99% NPV for NMIBC and MIBC, compared to 96% for a cystoscopy
- An exciting opportunity for GALEAS Bladder in surveillance settings, detecting bladder cancer when a cystoscopy delivered negative results.
Developed by our sister company Nonacus, GALEAS Bladder is available in the UK as part of an end-to-end clinical service delivered by Informed Genomics.
If you have any questions our service, please contact us
Find out more on our GALEAS Bladder Cancer service web page.
Complete this form to receive our white paper
“A recent breakthrough in diagnostics could make it easier to detect patients early”.